Skip to NavigationSkip to content

AbbVie's Skyrizi outpaces Novartis' Cosentyx in plaque psoriasis skin clearance

Published on 16/01/20 at 11:06am

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque psoriasis, hitting both its primary and all ranked secondary endpoints.

The data revealed “significantly higher” skin clearance rates for Skyrizi compared to Cosentyx, with 87% experiencing an improvement of at least 90% from baseline at 52 weeks of treatment, according to the Psoriasis Area and Severity Index (PASI), compared to just 57% with the latter.

Furthermore, 74% of patients also achieved a PASI90 score at 16 weeks of treatment compared to 66% with Cosentyx, meeting the trial’s second primary endpoint.

The findings also noted that Skyrizi outclassed Cosentyx in PASI100 and PASI75 scores, hitting all of the trial’s secondary endpoints.

"In this study, Skyrizi showed superior efficacy compared to Cosentyx in helping patients achieve and maintain high levels of skin clearance at week 52," commented Dr Michael Severino, Vice Chairman and President at AbbVie. "Head-to-head data like these are crucial to help patients and their doctors make informed treatment decisions. We are pleased to add these results to the growing body of evidence supporting Skyrizi as a differentiated treatment option for adults living with psoriasis."

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches